Mary L Stevenson1, Claire Q F Wang2, Melody Abikhair1, Nazanin Roudiani1, Diane Felsen3, James G Krueger2, Anna C Pavlick4, John A Carucci1. 1. Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, New York. 2. Laboratory for Investigative Dermatology, Rockefeller University, New York, New York. 3. Institute for Pediatric Urology, Weill Cornell Medicine, Cornell University, New York, New York. 4. Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York.
Abstract
IMPORTANCE: Limited therapies are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC). OBJECTIVE: To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC. DESIGN, SETTING, AND PARTICIPANTS: A single patient with locally advanced cSCC who declined surgery and radiotherapy underwent treatment with pembrolizumab, an anti-PD-1 antibody, at an academic dermatologic surgery section and cancer center. The patient was followed up for clinical and radiologic regression of cSCC. With the use of NanoString to amplify potential biomarkers, immunohistochemistry, and immunofluorescence, the ex vivo expression of PD-1 and a ligand (PD-L2) was assessed in 38 cSCC biopsy specimens from 24 patients with cSCC. Expression of PD-L1 and PD-L2 in the cSCC microenvironment was defined. INTERVENTION: Pembrolizumab, 2 mg/kg every 3 weeks, for 4 cycles. MAIN OUTCOMES AND MEASURES: Expression of PD-L1 and PD-L2 in the cSCC microenvironment. RESULTS: In 1 patient with locally advanced cSCC who was treated with pembrolizumab, nearly complete tumor regression was observed after 4 cycles of therapy. The NanoString technology used in 38 cSCC biopsy specimens from 24 patients with cSCC (19 men and 5 women; mean [SD] age, 76.4 [12.2] years) detected increased PD-1 and PD-L2 expression in high-risk cSCC. Immunohistochemical analysis confirmed enhanced expression of PD-1 and its ligands in cSCC with perineural invasion (mean [SEM] expression, 5.06 [1.27]; P = .05), superficial cSCC (mean [SEM] expression, 3.58 [1.50]; P = .15), organ transplant-associated cSCC (mean [SEM] expression, 3.01 [0.54]; P = .005), and infiltrative cSCC (mean [SD] expression, 2.01 [0.30]; P = .006) compared with normal skin specimens. In double-label immunofluorescence staining, CD11c+, a marker of myeloid dendritic cells, colocalized with PD-L1 and PD-L2 in cSCC lesions. CONCLUSIONS AND RELEVANCE: The favorable treatment response combined with significant involvement of PD-1 and PD ligands in cSCC lesions suggests that PD-1 blockade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further investigation in future clinical trials.
IMPORTANCE: Limited therapies are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC). OBJECTIVE: To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC. DESIGN, SETTING, AND PARTICIPANTS: A single patient with locally advanced cSCC who declined surgery and radiotherapy underwent treatment with pembrolizumab, an anti-PD-1 antibody, at an academic dermatologic surgery section and cancer center. The patient was followed up for clinical and radiologic regression of cSCC. With the use of NanoString to amplify potential biomarkers, immunohistochemistry, and immunofluorescence, the ex vivo expression of PD-1 and a ligand (PD-L2) was assessed in 38 cSCC biopsy specimens from 24 patients with cSCC. Expression of PD-L1 and PD-L2 in the cSCC microenvironment was defined. INTERVENTION: Pembrolizumab, 2 mg/kg every 3 weeks, for 4 cycles. MAIN OUTCOMES AND MEASURES: Expression of PD-L1 and PD-L2 in the cSCC microenvironment. RESULTS: In 1 patient with locally advanced cSCC who was treated with pembrolizumab, nearly complete tumor regression was observed after 4 cycles of therapy. The NanoString technology used in 38 cSCC biopsy specimens from 24 patients with cSCC (19 men and 5 women; mean [SD] age, 76.4 [12.2] years) detected increased PD-1 and PD-L2 expression in high-risk cSCC. Immunohistochemical analysis confirmed enhanced expression of PD-1 and its ligands in cSCC with perineural invasion (mean [SEM] expression, 5.06 [1.27]; P = .05), superficial cSCC (mean [SEM] expression, 3.58 [1.50]; P = .15), organ transplant-associated cSCC (mean [SEM] expression, 3.01 [0.54]; P = .005), and infiltrative cSCC (mean [SD] expression, 2.01 [0.30]; P = .006) compared with normal skin specimens. In double-label immunofluorescence staining, CD11c+, a marker of myeloid dendritic cells, colocalized with PD-L1 and PD-L2 in cSCC lesions. CONCLUSIONS AND RELEVANCE: The favorable treatment response combined with significant involvement of PD-1 and PD ligands in cSCC lesions suggests that PD-1 blockade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further investigation in future clinical trials.
Authors: Angela Steineck; Niklas Krumm; Jay F Sarthy; Colin C Pritchard; Teresa Chapman; Andrew W Stacey; Nicholas A Vitanza; Bonnie Cole Journal: JCO Precis Oncol Date: 2019-09-20
Authors: Melody Abikhair Burgo; Nazanin Roudiani; Jie Chen; Alexis L Santana; Nicole Doudican; Charlotte Proby; Diane Felsen; John A Carucci Journal: JCI Insight Date: 2018-09-06
Authors: Allen G Strickler; Payal Shah; Shirin Bajaj; Richard Mizuguchi; Rajiv I Nijhawan; Mercy Odueyungbo; Anthony Rossi; Désirée Ratner Journal: J Am Acad Dermatol Date: 2021-01-23 Impact factor: 15.487
Authors: Evi M Morandi; Tina Rauchenwald; Petra Puelzl; Bernhard W Zelger; Bettina G Zelger; Benjamin Henninger; Gerhard Pierer; Dolores Wolfram Journal: J Dtsch Dermatol Ges Date: 2021-11 Impact factor: 5.231
Authors: Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-05-24 Impact factor: 11.527